Pascal Laforet

4 Centre De Référence De Pathologie Neuromusculaire Paris Est
Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 265 publications

Recent advances in adult-onset disorders of muscle lipid metabolism.

Recent advances in adult-onset disorders of muscle lipid metabolism.

Journal: Current opinion in neurology

Published: August 27, 2026

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 31, 2026

A qualitative study of the discrepancy between patient expectations and assessment practices in 5q-adult spinal muscular atrophy in France.

A qualitative study of the discrepancy between patient expectations and assessment practices in 5q-adult spinal muscular atrophy in France.

Journal: Journal of neuromuscular diseases

Published: April 24, 2026

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Longitudinal Motor Function Changes in Adults With Late-Onset Pompe Disease: Key Determinants and Clinical Thresholds.

Longitudinal Motor Function Changes in Adults With Late-Onset Pompe Disease: Key Determinants and Clinical Thresholds.

Journal: Neurology

Published: March 05, 2026

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

Journal: European journal of neurology

Published: February 27, 2026

Feasibility and usefulness of personalised patient-reported outcome measures in the therapeutic follow-up of adult spinal muscular atrophy patients.

Feasibility and usefulness of personalised patient-reported outcome measures in the therapeutic follow-up of adult spinal muscular atrophy patients.

Journal: Clinical neurology and neurosurgery

Published: February 22, 2026

Prospective gait analysis in patients from the French registry of glycogen storage disease type III: implications for clinical trials.

Prospective gait analysis in patients from the French registry of glycogen storage disease type III: implications for clinical trials.

Journal: Journal of neurology

Published: February 20, 2026

Drug-induced autophagic myopathies: Exploring pathophysiology with immunolabelling and proteomics.

Drug-induced autophagic myopathies: Exploring pathophysiology with immunolabelling and proteomics.

Journal: Journal of neuropathology and experimental neurology

Published: January 29, 2026

Determinants of diaphragm ultrasound and its diagnostic performance for predicting respiratory status in myotonic dystrophy type 1.

Determinants of diaphragm ultrasound and its diagnostic performance for predicting respiratory status in myotonic dystrophy type 1.

Journal: Respiratory medicine and research

Published: January 17, 2026

Whole-Body Muscle MRI in Non-5q Spinal Muscular Atrophy: Patterns, Genotype Prediction, and Diagnostic Implications.

Whole-Body Muscle MRI in Non-5q Spinal Muscular Atrophy: Patterns, Genotype Prediction, and Diagnostic Implications.

Journal: Neurology. Genetics

Published: December 16, 2025

Real-Life Effectiveness After Switching to Avalglucosidase Alfa in Late-Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study.

Real-Life Effectiveness After Switching to Avalglucosidase Alfa in Late-Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study.

Journal: European journal of neurology

Published: November 23, 2025

Showing 1-12 of 265

Last Updated: 09/26/2026